Cheryl’s Liver Cancer Story
In my younger years, beginning around the age of 30, I was living fast and careless. I was the party girl, always drinking, never thinking about what it might one…
Continue Reading
Cheryl’s Liver Cancer Story
FDA Issues Complete Response Letter for Rivoceranib–Camrelizumab Combination in Advanced Liver Cancer
As reported by The Manila Times, the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Elevar Therapeutics regarding its new drug application for the…
Continue Reading
FDA Issues Complete Response Letter for Rivoceranib–Camrelizumab Combination in Advanced Liver Cancer
Combinatorial Immunotherapy Strategy: CatalYm Advances Visugromab in Advanced Liver Cancer
CatalYm has initiated patient enrollment in the GDFATHER-HCC-01 trial, a Phase 2b study investigating visugromab as part of a combinatorial treatment strategy for patients with unresectable or metastatic hepatocellular carcinoma…
Continue Reading
Combinatorial Immunotherapy Strategy: CatalYm Advances Visugromab in Advanced Liver Cancer
New Study Finds Keytruda Combo Falls Short of Expectations in Unresectable-Non-Metastatic Hepatocellular Carcinoma
There may be several reasons that HCC cancer of the liver cannot be removed. It may be due to the size of the tumor, or location proximity to major blood…
Continue Reading
New Study Finds Keytruda Combo Falls Short of Expectations in Unresectable-Non-Metastatic Hepatocellular Carcinoma
source: shutterstock.com
Toripalimab Combined with Bevacizumab Meets Primary Endpoint for Advanced Hepatocellular Carcinoma
Shanghai's Junshi Biosciences Co. (The Company) recently announced in Biospace, that its product, toripalimab (TUOYI®), combined with bevacizumab as a first-line therapy for hepatocellular carcinoma (HCC), met its endpoints in a…
Continue Reading
Toripalimab Combined with Bevacizumab Meets Primary Endpoint for Advanced Hepatocellular Carcinoma
source: shutterstock.com
ASCO GI Symposium: Fostrox-Lenvima Combo Treatment Show Clinical Benefit in Treating HCC
Despite novel treatment advances, hepatocellular carcinoma (HCC) remains difficult to treat. This aggressive cancer is often not found until later stages and not all people with HCC can utilize available…
Continue Reading
ASCO GI Symposium: Fostrox-Lenvima Combo Treatment Show Clinical Benefit in Treating HCC
source: pixabay.com
Positive Signs from Interim Data in Early Hepatocellular Carcinoma Trial
According to a story from PR Newswire, the pharma company Medivir AB, which is focused on developing cancer therapies in areas of critical high unmet need, recently announced the release…
Continue Reading
Positive Signs from Interim Data in Early Hepatocellular Carcinoma Trial
https://unsplash.com/photos/8ztH-7lj8ag
New Drug Combo Improves Survival in Inoperable Liver Cancer Patients
The success of the CARES 310 Trial Phase III (NCT03764293 ) was reported this week in Biospace by Elevar Therapeutics. The combination of two drugs, rivocera, and camrelizumab proved to…
Continue Reading
New Drug Combo Improves Survival in Inoperable Liver Cancer Patients
PublicDomainPictures / Pixabay
EGFR and ERBB2-Mutated HCC Responds Poorly to Lenvatinib
In the past, doctors have noticed a trend in hepatocellular carcinoma (HCC). More specifically, research has shown that HCC can grow resistant to certain drugs. This makes it more…
Continue Reading
EGFR and ERBB2-Mutated HCC Responds Poorly to Lenvatinib
OpenClipart-Vectors / Pixabay
YB-200 Granted Orphan Drug Designation for HCC
It can be difficult to spur interest in rare disease drug development. Forty years ago, the Orphan Drug Act passed as a way to incentivize drug development within this space.…
Continue Reading
YB-200 Granted Orphan Drug Designation for HCC
Source: Pixabay.com
Second-Line Lenvima Could Prolong HCC Survival
Despite medical advances and new therapeutic developments, hepatocellular carcinoma (HCC) remains difficult to treat; in part, this is due to the fact that HCC, like many liver cancers, is often…
Continue Reading
Second-Line Lenvima Could Prolong HCC Survival
source: unsplash.com
New Combination Therapy Approved in US for Unresectable Hepatocellular Carcinoma
According to a story from finance.yahoo.com, a new treatment regimen has been approved by the US Food and Drug Administration (FDA) for hepatocellular carcinoma that cannot be treated with surgery.…
Continue Reading
New Combination Therapy Approved in US for Unresectable Hepatocellular Carcinoma
Courtesy of Omega
INTERVIEW: Omega Therapeutics’ Mahesh Karande Discusses OTX-2002 for Hepatocellular Carcinoma
Mahesh Karande, the President and CEO of Omega Therapeutics, is incredibly passionate about epigenetics. And it shows: in the work that he and his team do, in the therapies they…
Continue Reading
INTERVIEW: Omega Therapeutics’ Mahesh Karande Discusses OTX-2002 for Hepatocellular Carcinoma
source: shutterstock
OTX-2002 for HCC Earns Orphan Drug Designation
The Orphan Drug Act was passed in 1983 to stimulate the development of therapeutics for rare diseases. With this came the Orphan Drug designation. This designation is granted to drugs…
Continue Reading
OTX-2002 for HCC Earns Orphan Drug Designation
source: pixabay.com
Study of the Week: Could This Protein Predict Diabetes and Cancer Death Risk?
Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…
Continue Reading
Study of the Week: Could This Protein Predict Diabetes and Cancer Death Risk?
source: pixabay.com
Combination Therapy for Hepatocellular Carcinoma Fails to Achieve Trial Endpoints
According to a story from Market Watch, the drug companies Merch and Eisai recently announced an update on their phase 3 clinical trial. This clinical trial was evaluating a combination…
Continue Reading
Combination Therapy for Hepatocellular Carcinoma Fails to Achieve Trial Endpoints
source: pixabay.com
Porphyria Increases Liver Cancer Risk by 5%, Study Shows
Sometimes, certain health conditions can increase the risk of developing other conditions. According to a new research study, this may be the case with porphyria and hepatocellular carcinoma. An article…
Continue Reading
Porphyria Increases Liver Cancer Risk by 5%, Study Shows
Patients with Liver Diseases Causing Cirrhosis May Be Predisposed to HCC
Liver cirrhosis (scarring) can be fatal because damage to the liver is irreversible. A cirrhotic liver leads to liver failure, liver cancer, and eventually death. According to a report in…
Continue Reading
Patients with Liver Diseases Causing Cirrhosis May Be Predisposed to HCC
source: pixabay.com
ET140203, ECT204 Earn Orphan Drug Designation for Hepatocellular Carcinoma
In a news release from early February 2022, clinical-stage biotechnology company Eureka Therapeutics, Inc. (“Eureka”) shared that two of its therapies – ET140203 and ECT204 – received Orphan Drug designation…
Continue Reading
ET140203, ECT204 Earn Orphan Drug Designation for Hepatocellular Carcinoma
source: pixabay.com
LioCyx-M004 for HBV-Related Hepatocellular Carcinoma Earns Fast Track Designation
According to Healio, the U.S. Food and Drug Administration (FDA) recently granted Fast Track designation to LioCyx-M004. This therapy, developed by T-cell immunotherapy company Lion TCR, is designed to…
Continue Reading
LioCyx-M004 for HBV-Related Hepatocellular Carcinoma Earns Fast Track Designation
source: pixabay.com
CRISPR/Cas9 Gene Editing Adds Ultrasound Therapy for Hepatocellular Carcinoma to its List of Possibilities
Washington University Researchers readily acknowledge the attributes of sonodynamic therapy (SDT) as a promising therapeutic method to treat hepatocellular carcinoma (HCC). SDT is noninvasive with high tissue penetration, but…
Continue Reading
CRISPR/Cas9 Gene Editing Adds Ultrasound Therapy for Hepatocellular Carcinoma to its List of Possibilities
[Source: pixabay.com]
KEYTRUDA Met OS Endpoint in Hepatocellular Carcinoma Clinical Trial
Clinical trials have many endpoints - or milestones they are looking to achieve. These endpoints help signify the safety, efficacy, and tolerability of the treatments. In the Phase 3…
Continue Reading
KEYTRUDA Met OS Endpoint in Hepatocellular Carcinoma Clinical Trial
Atezolizumab and Bevacizumab Improves Survival With Unresectable Hepatocellular Carcinoma
New treatments for unresectable hepatocellular carcinoma (HCC) were approved based on a Phase 3 clinical trial. Richard Kim has recently provided an overview of this study. The Study This study ultimately…
Continue Reading
Atezolizumab and Bevacizumab Improves Survival With Unresectable Hepatocellular Carcinoma
source: pixabay.com
Could Hepatocellular Carcinoma Cause One Million Deaths Annually by 2030?
Thanks to advances in immunotherapy, liver cancer (Hepatocellular carcinoma-HCC) has seen a rise in treatment options for patients in advanced stages of the disease. HCC is one of the…
Continue Reading
Could Hepatocellular Carcinoma Cause One Million Deaths Annually by 2030?
source: pixabay.com
Hepatocellular Carcinoma Gene Study Unveils New Potential Drug Target
According to a study published in PLOS Genetics, a recent genetic study of hepatocellular carcinoma (HCC) cancer tumors has revealed vital information that could one day lead to a new…
Continue Reading
Hepatocellular Carcinoma Gene Study Unveils New Potential Drug Target
